Board of Directors
Hoyoung Huh has served as our Chairman since September 2011. Dr. Huh was Executive Chairman from February 2011 to September 2011 and a director since May 2010. He is Chairman of the board of directors of Cytomx Therapeutics, Inc. and a director of ADDEX Pharmaceuticals. From February 2008 to December 2011, Dr. Huh was Chairman of the board of directors of BiPar Sciences, Inc., a wholly-owned subsidiary and west coast innovation center for sanofi-aventis since the April 2009 merger, and served as BiPar’s president and Chief Executive Officer from February 2008 until December 2009. He also serves on the boards of directors of several privately-held companies. Dr. Huh served on the board of directors of Facet Biotech from September 2009 to April 2010 and was President and Chief Executive Officer of BiPar Sciences from February 2008 to January 2010. He was a member of the board of directors, Chief Operating Officer, and head of the PEGylation business unit at Nektar Therapeutics. Dr. Huh was a partner at McKinsey & Company, where he was in the biotechnology and biopharmaceutical sectors from 1997 to 2004. Prior to McKinsey, he held positions as a physician and researcher at Cornell University Medical College and Sloan-Kettering Cancer Center. Dr. Huh holds an A.B. in biochemistry from Dartmouth College and an M.D. and Ph.D. from Cornell University Medical College and Sloan-Kettering Institute.
Mr. Bradbury has served as our director since September 2012. He serves as a member of the boards of directors of Illumina, Inc., Corcept Therapeutics and BioMed Realty, as well as on the board of trustees for the Keck Graduate Institute. He also serves on the University of California San Diego, Rady School of Management’s Advisory Council, the University of Miami’s Innovation Corporate Advisory Council, Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin’s President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003 and in other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury served as a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, holding a number of sales and marketing positions. Mr. Bradbury serves on the University of California San Diego, Rady School of Management’s Advisory Council, RAND Health Board of Advisors and University of Miami’s Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Karin Eastham has served as our director since March 2009. She also serves as a director of MorphoSys AG, Illumina Inc., Trius Therapeutics, Inc., as well as the privately-held company Veracyte. Ms. Eastham also recently served as a director of Amylin Pharmaceuticals, Inc., from 2005 until its sale in 2011, Genoptix, Inc. from 2008 until its sale in 2011. and several non-profit organizations including UCSD Moores Cancer Center and Corporate Directors Forum. From May 2004 to September 2008, Ms. Eastham served as Executive Vice President and Chief Operating Officer and a member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation, engaged in medical research. From April 1999 to May 2004, Ms. Eastham served as Senior Vice President, Finance and Chief Financial Officer of Diversa Corporation. From April 1997 to April 1999, Ms. Eastham served as Vice President, Finance and Administration and Chief Financial Officer for CombiChem, Inc. From October 1992 to April 1997, Ms. Eastham served as Vice President, Finance and Administration and Chief Financial Officer for Cytel Corporation. Ms. Eastham also held several similar positions with other companies, including Vice President, Finance, at Boehringer Mannheim Diagnostics from 1976 to 1988. Ms. Eastham holds a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant and a Certified Director.
Thomas Hofstaetter has served as our director since March 2010. From November 2009 to December 2011, he was President, Chief Executive Officer and a director of VaxInnate Corporation. From September 2004 to October 2009, Dr. Hofstaetter was Senior Vice President, Corporate Development and Head of Global Business Development and a member of the Wyeth Management Committee at Wyeth, Inc. From December 1999 to August 2004, Dr. Hofstaetter was Senior Vice President of Corporate Development of Aventis. From 1991 to 1999, Dr. Hofstaetter served in various executive managerial positions around the world, including the United States, Japan, France and his native Germany, with Hoescht Pharma, where he served as a member of the integration steering committee when Aventis was created from the merger between Hoescht and Rhone-Poulenc Rorer. In 1978, Dr. Hofstaetter joined Behringwerke AG in Germany as a research scientist and rose to become head of Research in 1988 and head of the Immunology/Oncology business unit in 1989. Dr. Hofstaetter holds a Master of Science degree in Biochemistry and a Ph.D. in Molecular Biology, magna cum laude, from the University of Tuebingen in Germany.
V. Bryan Lawlis has served as our director since March 2012. He is a founder and currently serves as the President, Chief Executive Officer and a director of Itero Biopharmaceuticals, LLC, a privately held biopharmaceutical company focused on the cost-efficient development and commercialization of protein therapeutics. Dr. Lawlis also serves on the boards of BioMarin Pharmaceutical Inc. and Sutro Biopharma, Inc. Prior to Itero, Dr. Lawlis was an officer of Aradigm Corporation between November 2001 and August 2006, where he functioned in several roles, including as President and Chief Executive Officer and a member of its board of directors. Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999 and Chairman from 1999 to 2001, until it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed by Genencor, Inc. and Genentech, Inc. in various roles. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in Biochemistry from Washington State University.
Dr. Molineaux has served as our director since September 2012. She serves as Chief Executive Officer and President of Calithera Biosciences, Inc., which she co-founded in June 2010. Prior to Calithera, Dr. Molineaux co-founded Proteolix, Inc. where she served as Chief Scientific Officer from December 2003 until December 2005 and from February 2009 until November 2009, and as President and Chief Executive Officer from January 2006 until February 2009. Dr. Molineaux was responsible for leading the development of Proteolix’s second generation proteasome inhibitor, carfilzomib (now marketed as Kryprolis), for the treatment of multiple myeloma, from discovery through completion of clinical trials for accelerated approval, until the company’s acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From 2000 to 2003, Dr. Molineaux served as Vice President of Biology at Rigel Pharmaceuticals, Inc. She served as Vice President of Biology at Praelux, Inc. from 1999 to 2000, and from 1994 through 1999, as Vice President of Drug Development at Praecis Pharmaceuticals, Inc. From 1989 until 1994, she was a scientist in the Immunology group at Merck & Co. Dr. Molineaux holds a B.S. degree in Biology from Smith College and a Ph.D. degree in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University. She currently serves as the Co-Vice Chair of Bay Bio, Northern California’s Life Science Association, and as a member of the board of directors of We Teach Science, a San Francisco Bay Area mentoring program for students in math and science.
John A. Scarlett has served as our Chief Executive Officer and director since September 2011 and President since January 2012. Prior to joining Geron, Dr. Scarlett served as President, Chief Executive Officer and a member of the board of directors of Proteolix, Inc. from February 2009 until its acquisition by Onyx Pharmaceuticals, Inc. in November 2009. From February 2002 until its acquisition by Ipsen, S.A. in October 2008, Dr. Scarlett served as the Chief Executive Officer and a member of the board of directors of Tercica, Inc. and also as its President from February 2002 through February 2007. From March 1993 to May 2001, Dr. Scarlett served as President and Chief Executive Officer of Sensus Drug Development Corporation. In 1995, he co-founded Covance Biotechnology Services, Inc. and served as a member of its board of directors from inception to 2000. From 1991 to 1993, Dr. Scarlett headed the North American Clinical Development Center and served as Senior Vice President of Medical and Scientific Affairs at Novo Nordisk Pharmaceuticals, Inc., a wholly owned subsidiary of Novo Nordisk A/S. Dr. Scarlett received his B.A. degree in chemistry from Earlham College and his M.D. from the University of Chicago, Pritzker School of Medicine.
Robert J. Spiegel has served as our director since May 2010. Dr. Spiegel currently serves as Chief Medical Officer of PTC Therapeutics, Inc. He is also a director of Edge Therapeutics and Avior Computing Corporation. After 26 years with the Schering-Plough Corporation, Dr. Spiegel retired in 2009 as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. He initially joined Schering-Plough as Director of clinical research for oncology and rose to hold various positions including Senior Vice President of worldwide clinical research. Following a residency in internal medicine, he completed a fellowship in medical oncology at the National Cancer Institute and held academic positions at the National Cancer Institute and New York University Cancer Center. He is currently an Associate Professor at Weill Cornell Medical College and serves on the Scientific Advisory Committees of a number of companies. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.